

Brazikumab Biosimilar - Research Grade

Product Code: ICH5413

More Information

Species Reactivity: Human

Target: IL23A p19

Concentration: 5mg/ml

Isotype: IgG2 - lambda

Host: CHO Cells

product name H2: Brazikumab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q9NPF7

Shipping Conditions: Blue ice

background: Interleukin-23 subunit p19 (IL23A) drives Th17 responses and is a key cytokine target in inflammatory bowel disease and psoriasis research. This product is an unconjugated, non-therapeutic analog of brazikumab, a human IgG2-lambda recombinant antibody for research use only. It is supplied with low endotoxin to in vivo-grade standards and produced in scalable milligram-to-gram quantities for bulk and high-throughput laboratories. Applications include functional and neutralization assays, IL-23/Th17 signaling studies, in vitro screening and preclinical autoimmune-inflammation models examining the IL-23 p19 subunit. Built for in vivo use with low endotoxin and scalable milligram-to-gram supply, it remains a reliable choice for bulk research applications.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks